Literature DB >> 22571976

Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.

Rudolf Moldzio1, Thomas Pacher, Christopher Krewenka, Barbara Kranner, Johannes Novak, Johanna Catharina Duvigneau, Wolf-Dieter Rausch.   

Abstract

Cannabinoids derived from Cannabis sativa demonstrate neuroprotective properties in various cellular and animal models. Mitochondrial impairment and consecutive oxidative stress appear to be major molecular mechanisms of neurodegeneration. Therefore we studied some major cannabinoids, i.e. delta-9-tetrahydrocannabinolic acid (THCA), delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in mice mesencephalic cultures for their protective capacities against 1-methyl-4-phenyl pyridinium (MPP(+)) toxicity. MPP(+) is an established model compound in the research of parkinsonism that acts as a complex I inhibitor of the mitochondrial respiratory chain, resulting in excessive radical formation and cell degeneration. MPP(+) (10 μM) was administered for 48 h at the 9th DIV with or without concomitant cannabinoid treatment at concentrations ranging from 0.01 to 10 μM. All cannabinoids exhibited in vitro antioxidative action ranging from 669 ± 11.1 (THC), 16 ± 3.2 (THCA) to 356 ± 29.5 (CBD) μg Trolox (a vitamin E derivative)/mg substance in the 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay. Cannabinoids were without effect on the morphology of dopaminergic cells stained by tyrosine hydroxylase (TH) immunoreaction. THC caused a dose-dependent increase of cell count up to 17.3% at 10 μM, whereas CBD only had an effect at highest concentrations (decrease of cell count by 10.1-20% at concentrations of 0.01-10 μM). It influenced the viability of the TH immunoreactive neurons significantly, whereas THCA exerts no influence on dopaminergic cell count. Exposure of cultures to 10 μM of MPP(+) for 48 h significantly decreased the number of TH immunoreactive neurons by 44.7%, and shrunken cell bodies and reduced neurite lengths could be observed. Concomitant treatment of cultures with cannabinoids rescued dopaminergic cells. Compared to MPP(+) treated cultures, THC counteracted toxic effects in a dose-dependent manner. THCA and CBD treatment at a concentration of 10 μM lead to significantly increased cell counts to 123% and 117%, respectively. Even though no significant preservation or recovery of neurite outgrowth to control values could be observed, our data show that cannabinoids THC and THCA protect dopaminergic neurons against MPP(+) induced cell death.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571976     DOI: 10.1016/j.phymed.2012.04.002

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  23 in total

Review 1.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

2.  Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Authors:  Xavier Nadal; Carmen Del Río; Salvatore Casano; Belén Palomares; Carlos Ferreiro-Vera; Carmen Navarrete; Carolina Sánchez-Carnerero; Irene Cantarero; Maria Luz Bellido; Stefan Meyer; Gaetano Morello; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739

Review 3.  The cannabinoid acids, analogs and endogenous counterparts.

Authors:  Sumner H Burstein
Journal:  Bioorg Med Chem       Date:  2014-04-01       Impact factor: 3.641

4.  Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.

Authors:  Joëlle Nader; Cinzia Rapino; Benjamin Gennequin; Francois Chavant; Maureen Francheteau; Alexandros Makriyannis; Andrea Duranti; Mauro Maccarrone; Marcello Solinas; Nathalie Thiriet
Journal:  Neuropharmacology       Date:  2014-04-05       Impact factor: 5.250

Review 5.  Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Mol Neurodegener       Date:  2015-04-08       Impact factor: 14.195

6.  Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase.

Authors:  Ji Jia; Lei Ma; Mingchun Wu; Lei Zhang; Xiajing Zhang; Qian Zhai; Tao Jiang; Qiang Wang; Lize Xiong
Journal:  Oxid Med Cell Longev       Date:  2014-07-17       Impact factor: 6.543

7.  A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors.

Authors:  Carolina Echeverry; Giselle Prunell; Camila Narbondo; Verónica Sánchez de Medina; Xavier Nadal; Miguel Reyes-Parada; Cecilia Scorza
Journal:  Neurotox Res       Date:  2020-09-04       Impact factor: 3.911

8.  New Insights on Hemp Oil Enriched in Cannabidiol: Decarboxylation, Antioxidant Properties and In Vitro Anticancer Effect.

Authors:  Anca Roxana Petrovici; Natalia Simionescu; Andreea Isabela Sandu; Vasile Paraschiv; Mihaela Silion; Mariana Pinteala
Journal:  Antioxidants (Basel)       Date:  2021-05-07

9.  CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120.

Authors:  Shuxian Hu; Wen S Sheng; R Bryan Rock
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.

Authors:  Wendy Swift; Alex Wong; Kong M Li; Jonathon C Arnold; Iain S McGregor
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.